Engin Elif
Stress Neurobiology Laboratory, Division of Basic Neuroscience, McLean Hospital, Belmont, MA, United States.
Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
Front Psychiatry. 2023 Jan 12;13:1060949. doi: 10.3389/fpsyt.2022.1060949. eCollection 2022.
Benzodiazepines have been in use for over half a century. While they remain highly prescribed, their unfavorable side-effect profile and abuse liability motivated a search for alternatives. Most of these efforts focused on the development of benzodiazepine-like drugs that are selective for specific GABA receptor subtypes. While there is ample evidence that subtype-selective GABA receptor ligands have great potential for providing symptom relief without typical benzodiazepine side-effects, it is less clear whether subtype-selective targeting strategies can also reduce misuse and abuse potential. This review focuses on the three benzodiazepine properties that are relevant to the DSM-5-TR criteria for Sedative, Hypnotic, or Anxiolytic Use Disorder, namely, reinforcing properties of benzodiazepines, maladaptive behaviors related to benzodiazepine use, and benzodiazepine tolerance and dependence. We review existing evidence regarding the involvement of different GABA receptor subtypes in each of these areas. The reviewed studies suggest that α1-containing GABA receptors play an integral role in benzodiazepine-induced plasticity in reward-related brain areas and might be involved in the development of tolerance and dependence to benzodiazepines. However, a systematic comparison of the contributions of all benzodiazepine-sensitive GABA receptors to these processes, a mechanistic understanding of how the positive modulation of each receptor subtype might contribute to the brain mechanisms underlying each of these processes, and a definitive answer to the question of whether specific chronic modulation of any given subtype would result in some or all of the benzodiazepine effects are currently lacking from the literature. Moreover, how non-selective benzodiazepines might lead to the maladaptive behaviors listed in DSM and how different GABA receptor subtypes might be involved in the development of these behaviors remains unexplored. Considering the increasing burden of benzodiazepine abuse, the common practice of benzodiazepine misuse that leads to severe dependence, and the current efforts to generate side-effect free benzodiazepine alternatives, there is an urgent need for systematic, mechanistic research that provides a better understanding of the brain mechanisms of benzodiazepine misuse and abuse, including the involvement of specific GABA receptor subtypes in these processes, to establish an informed foundation for preclinical and clinical efforts.
苯二氮䓬类药物已经使用了半个多世纪。尽管它们仍然被大量处方,但因其不良的副作用和滥用倾向,促使人们寻找替代品。这些努力大多集中在开发对特定GABA受体亚型具有选择性的苯二氮䓬类药物。虽然有充分的证据表明,亚型选择性GABA受体配体在提供症状缓解方面具有巨大潜力,且无典型的苯二氮䓬类药物副作用,但尚不清楚亚型选择性靶向策略是否也能降低误用和滥用的可能性。本综述聚焦于与《精神疾病诊断与统计手册》第5版修订版(DSM-5-TR)中镇静、催眠或抗焦虑药物使用障碍标准相关的苯二氮䓬类药物的三个特性,即苯二氮䓬类药物的强化特性、与苯二氮䓬类药物使用相关的适应不良行为,以及苯二氮䓬类药物的耐受性和依赖性。我们综述了现有证据,以了解不同GABA受体亚型在这些领域中的作用。所综述的研究表明,含α1的GABA受体在苯二氮䓬类药物诱导的与奖赏相关脑区的可塑性中起重要作用,可能参与苯二氮䓬类药物耐受性和依赖性的形成。然而,目前文献中缺乏对所有苯二氮䓬类药物敏感的GABA受体对这些过程贡献的系统比较,缺乏对每种受体亚型的正向调节如何可能促成这些过程背后的脑机制的机制性理解,也缺乏对特定慢性调节任何给定亚型是否会导致部分或全部苯二氮䓬类药物效应这一问题的确切答案。此外,非选择性苯二氮䓬类药物如何导致DSM中列出的适应不良行为,以及不同GABA受体亚型如何参与这些行为的形成仍未得到探索。考虑到苯二氮䓬类药物滥用的负担日益加重、导致严重依赖的苯二氮䓬类药物误用的普遍现象,以及目前为开发无副作用的苯二氮䓬类药物替代品所做的努力,迫切需要进行系统的、机制性的研究,以更好地理解苯二氮䓬类药物误用和滥用的脑机制,包括特定GABA受体亚型在这些过程中的作用,从而为临床前和临床研究奠定明智的基础。